PCRX — Pacira Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $1.02bn
- $1.15bn
- $700.97m
- 94
- 76
- 76
- 96
Annual cashflow statement for Pacira Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 146 | 42 | 15.9 | 42 | -99.6 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 72 | 69.8 | 62.2 | 67.3 | 208 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -33.8 | -25.5 | -16.4 | -45.8 | -18.5 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 77 | 126 | 145 | 155 | 189 |
| Capital Expenditures | -37.8 | -45.9 | -30.1 | -15.2 | -10.6 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -240 | 25.1 | -195 | 92.7 | -72.6 |
| Acquisition of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -278 | -20.8 | -225 | 77.5 | -83.3 |
| Financing Cash Flow Items | -38.7 | -5.17 | 0 | -5.86 | -27.2 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 222 | 381 | -402 | -183 | 17.4 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 21.7 | 486 | -481 | 49.2 | 123 |